Szulkin, RobertKarlsson, RobertWhitington, ThomasAly, MarkusGronberg, HenrikEeles, RosalindEaston, DouglasKote-Jarai, ZsofiaOlama, Ali Amin AlBenlloch, SaraMuir, KennethGiles, GrahamSouthey, MelissaFitzGerald, LieselHenderson, BrianSchumacher, FredrickHaiman, ChristopherSipeky, CsillaTammela, Teuvo L. J.Nordestgaard, Børge G.Key, TimothyTravis, RuthNeal, DavidDonovan, JennyHamdy, FreddiePharoah, Paul D. P.Pashayan, NoraKhaw, Kay-TeeStanford, JanetThibodeau, StephenMcDonnell, ShannonSchaid, DanielMaier, ChristianeVogel, WaltherLuedeke, ManuelHerkommer, KathleenKibel, AdamCybulski, CezaryLubiński, JanKluźniak, WojciechCannon-Albright, LisaBrenner, HermannHerrmann, VolkerHolleczek, BerndPark, JongSellers, ThomasLim, Hui-YiSlavov, ChavdarKaneva, RadkaMitev, VanioSpurdle, AmandaTeixeira, ManuelPaulo, PaulaMaia, SofiaPandha, HardevMichael, AgnieszkaKierzek, AndrzejBatra, JyotsnaClements, JudithAlbanes, DemetriusAndriole, GeraldBerndt, SonjaChanock, StephenGapstur, SusanGiovannucci, EdwardHunter, DavidKraft, PeterLe Marchand, LoicMa, JingMondul, AlisonPenney, KathrynStampfer, MeirStevens, VictoriaWeinstein, StephanieTrichopoulou, AntoniaBueno-de-Mesquita, BasTjonneland, AnneCox, DavidMaehle, LoviseSchleutker, JohannaLindström, SaraWiklund, Fredrik2019-09-052015Szulkin, R., R. Karlsson, T. Whitington, M. Aly, H. Gronberg, R. A. Eeles, D. F. Easton, et al. 2015. “Genome-Wide Association Study of Prostate Cancer-Specific Survival.” Cancer Epidemiology Biomarkers & Prevention 24 (11): 1796–1800. https://doi.org/10.1158/1055-9965.epi-15-0543.1055-99651538-7755http://nrs.harvard.edu/urn-3:HUL.InstRepos:41292457Background: Unnecessary intervention and overtreatment of indolent disease are common challenges in clinical management of prostate cancer. Improved tools to distinguish lethal from indolent disease are critical. Methods: We performed a genome-wide survival analysis of cause-specific death in 24,023 prostate cancer patients (3,513 disease-specific deaths) from the PRACTICAL and BPC3 consortia. Top findings were assessed for replication in a Norwegian cohort (CONOR). Results: We observed no significant association between genetic variants and prostate cancer survival. Conclusions: Common genetic variants with large impact on prostate cancer survival were not observed in this study.Impact: Future studies should be designed for identification of rare variants with large effect sizes or common variants with small effect sizes.en-USJournal Article2019-09-0510.1158/1055-9965.EPI-15-0543